Health Economics & Outcomes Research (HEOR)

Analysis Group is distinguished by our understanding of health economics and outcomes. We collaborate with many clients to develop and implement HEOR strategies to support pharmaceutical products throughout their life cycles. Our expertise includes comprehensive research capabilities, defined by cutting-edge methodologies that draw on diverse data sources from U.S. and global markets. Our studies have involved diverse geographies, including Argentina, Australia, Brazil, Canada, China, Colombia, France, Germany, Finland, Israel, Japan, Mexico, Portugal, Saudi Arabia, Scotland, South Korea, Spain, Sweden, Taiwan, the U.K., and the United States.

We have developed different types of models to address clients’ needs, including budget impact models to assess the economic implications of new formulary cost-minimization, cost-utility, and cost-effectiveness to compare a client’s drugs to comparators, and simple cost calculators to evaluate the costs of treatments
and costs of adverse events.

Our
privacy policy and terms of use on our website have changed. Additionally, this website uses cookies to analyze traffic and help us improve the user experience of the site. Please review our
privacy policy and
terms regarding cookies for additional information. By continuing to use this site you agree to the privacy policy and terms of use, including the use of cookies.